

Jeanette Lundin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4537327/jeanette-lundin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

956
citations

8
h-index

23
g-index

23
ext. papers

1,072
ext. citations

3.5
avg, IF

2.95
L-index

#	Paper	IF	Citations
22	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions: Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. <i>EJHaem</i> , 2021 , 2, 525-529	0.9	0
21	Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. <i>British Journal of Haematology</i> , 2020 , 191, 426-432	4.5	1
20	Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies. <i>Journal of Immunological Methods</i> , 2020 , 476, 112675	2.5	3
19	Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. <i>Haematologica</i> , 2019 , 104, e208-e210	6.6	32
18	Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. <i>British Journal of Haematology</i> , 2018 , 183, 212-224	4.5	11
17	Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study. <i>British Journal of Haematology</i> , 2018 , 182, 590-594	4.5	2
16	Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 91-102	7.4	7
15	Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2016 , 128, 3235-3235	2.2	2
14	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. <i>Haematologica</i> , 2016 , 101, 1573-1580	6.6	88
13	Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program. <i>Blood</i> , 2015 , 126, 1745-1745	2.2	3
12	In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study. <i>Blood</i> , 2015 , 126, 4164-4164	2.2	3
11	A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update. <i>Blood</i> , 2015 , 126, 1734-1734	2.2	
10	Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. <i>Medical Oncology</i> , 2006 , 23, 137-9	3.7	4
9	Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).. <i>Blood</i> , 2005 , 106, 2967-2967	2.2	1
8	Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2005 , 106, 2986-2986	2.2	
7	Therapy for mycosis fungoides. <i>Current Treatment Options in Oncology</i> , 2004 , 5, 203-14	5.4	11
6	Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. <i>Seminars in Hematology</i> , 2004 , 41, 234-45	4	14

5	T-Cell Function in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Following Alemtuzumab (Campath [®]) or Fludarabine Treatment.. <i>Blood</i> , 2004 , 104, 2513-2513	2.2	
4	Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. <i>Blood</i> , 2003 , 101, 4267-72	2.2	326
3	Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III. <i>The Hematology Journal</i> , 2003 , 4, 248-52		7
2	Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2002 , 100, 768-73 ^{2,2}		422
1	The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma. <i>European Journal of Haematology</i> , 1999 , 63, 163-70	3.8	19